Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning - PubMed (original) (raw)
Clinical Trial
. 2007 Feb;60(2 Suppl 1):ONS89-98; discussion ONS98-9.
doi: 10.1227/01.NEU.0000249256.09289.5F.
Affiliations
- PMID: 17297371
- DOI: 10.1227/01.NEU.0000249256.09289.5F
Clinical Trial
Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning
John H Sampson et al. Neurosurgery. 2007 Feb.
Abstract
Objective: Convection-enhanced delivery (CED) holds tremendous potential for drug delivery to the brain. However, little is known about the volume of distribution achieved within human brain tissue or how target anatomy and catheter positioning influence drug distribution. The primary objective of this study was to quantitatively describe the distribution of a high molecular weight agent by CED relative to target anatomy and catheter position in patients with malignant gliomas.
Methods: Seven adult patients with recurrent malignant gliomas underwent intracerebral infusion of the tumor-targeted cytotoxin, cintredekin besudotox, concurrently with 123I-labeled human serum albumin. High-resolution single-photon emission computed tomographic images were obtained at 24 and 48 hours and were coregistered with magnetic resonance imaging scans. The distribution of 123I-labeled human serum albumin relative to target anatomy and catheter position was analyzed.
Results: Intracerebral CED infusions were well-tolerated and some resulted in a broad distribution of 123I-labeled human serum albumin, but target anatomy and catheter positioning had a significant influence on infusate distribution even within non-contrast-enhancing areas of brain. Intratumoral infusions were anisotropic and resulted in limited coverage of the enhancing tumor area and adjacent peritumoral regions.
Conclusions: CED has the potential to deliver high molecular weight agents into tumor-infiltrated brain parenchyma with volumes of distribution that are clinically relevant. Target tissue anatomy and catheter position are critical parameters in optimizing drug delivery.
Similar articles
- Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.
Kunwar S, Chang SM, Prados MD, Berger MS, Sampson JH, Croteau D, Sherman JW, Grahn AY, Shu VS, Dul JL, Husain SR, Joshi BH, Pedain C, Puri RK. Kunwar S, et al. Neurosurg Focus. 2006 Apr 15;20(4):E15. Neurosurg Focus. 2006. PMID: 16709020 Clinical Trial. - Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin.
Sampson JH, Raghavan R, Provenzale JM, Croteau D, Reardon DA, Coleman RE, Rodríguez Ponce I, Pastan I, Puri RK, Pedain C. Sampson JH, et al. AJR Am J Roentgenol. 2007 Mar;188(3):703-9. doi: 10.2214/AJR.06.0428. AJR Am J Roentgenol. 2007. PMID: 17312057 - Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK; Cintredekin Besudotox Intraparenchymal Study Group. Kunwar S, et al. J Clin Oncol. 2007 Mar 1;25(7):837-44. doi: 10.1200/JCO.2006.08.1117. J Clin Oncol. 2007. PMID: 17327604 Clinical Trial. - Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.
Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK. Kioi M, et al. Technol Cancer Res Treat. 2006 Jun;5(3):239-50. doi: 10.1177/153303460600500307. Technol Cancer Res Treat. 2006. PMID: 16700620 Review. - Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors.
Ferguson S, Lesniak MS. Ferguson S, et al. Curr Drug Deliv. 2007 Apr;4(2):169-80. doi: 10.2174/156720107780362302. Curr Drug Deliv. 2007. PMID: 17456036 Review.
Cited by
- The Relation between Catheter Occlusion and Backflow during Intraparenchymal Cerebral Infusions.
Brady ML, Raghavan R, Block W, Grabow B, Ross C, Kubota K, Alexander AL, Emborg ME. Brady ML, et al. Stereotact Funct Neurosurg. 2015;93(2):102-109. doi: 10.1159/000367665. Epub 2015 Feb 18. Stereotact Funct Neurosurg. 2015. PMID: 25721097 Free PMC article. - A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.
Nguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, Larson SM, Debinski W, Mintz A. Nguyen V, et al. Neuro Oncol. 2012 Oct;14(10):1239-53. doi: 10.1093/neuonc/nos211. Epub 2012 Sep 5. Neuro Oncol. 2012. PMID: 22952195 Free PMC article. - Convection Enhanced Delivery in the Setting of High-Grade Gliomas.
Nwagwu CD, Immidisetti AV, Jiang MY, Adeagbo O, Adamson DC, Carbonell AM. Nwagwu CD, et al. Pharmaceutics. 2021 Apr 15;13(4):561. doi: 10.3390/pharmaceutics13040561. Pharmaceutics. 2021. PMID: 33921157 Free PMC article. Review. - Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas.
Chittiboina P, Heiss JD, Warren KE, Lonser RR. Chittiboina P, et al. J Neurosurg Pediatr. 2014 Mar;13(3):276-82. doi: 10.3171/2013.11.PEDS136. Epub 2014 Jan 10. J Neurosurg Pediatr. 2014. PMID: 24410126 Free PMC article. - Current status of intratumoral therapy for glioblastoma.
Mehta AI, Linninger A, Lesniak MS, Engelhard HH. Mehta AI, et al. J Neurooncol. 2015 Oct;125(1):1-7. doi: 10.1007/s11060-015-1875-1. Epub 2015 Aug 2. J Neurooncol. 2015. PMID: 26233248
Publication types
MeSH terms
Substances
Grants and funding
- 2P50-NS20023/NS/NINDS NIH HHS/United States
- 5P50-CA108786/CA/NCI NIH HHS/United States
- K23 RR16065/RR/NCRR NIH HHS/United States
- R01 CA097611/CA/NCI NIH HHS/United States
- S10 RR15697/RR/NCRR NIH HHS/United States
- Intramural NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical